Orlistat-d3

• Target:

  Apoptosis|||Fatty Acid Synthase

• Related Pathways:

  Metabolism|||Apoptosis

• Bioactivity:

  Orlistat-d3 is intended for use as an internal standard for the quantification of orlistat by GC- or LC-MS. Orlistat is a digestive lipase inhibitor. It inhibits diacylglycerol lipase ? (DAGL?), DAGL?, ?/?-hydrolase domain-containing protein 12 (ABHD12), ABHD16A, and platelet-activating factor acetylhydrolase (PAF-AH; IC50s = 0.06, 0.1, 0.08, 0.03, and 0.05 µM, respectively), as well as pancreatic lipase and hormone-sensitive lipase (IC50s = 0.65 and 2.1 µg/ml, respectively) but does not inhibit fatty acid amide hydrolase (FAAH) or KIAA1363 (IC50s = >100 µM for both) . Orlistat decreases ionomycin-induced production of the endocannabinoid 2-arachidonoyl glycerol (2-AG) in N18TG2 murine neuroblastoma cells when used at a concentration of 1 µM. It also inhibits fatty acid synthase (FASN; Kiapp = ~0.1 µM for the human enzyme) and the proliferation of PC3 prostate cancer cells in a concentration-dependent manner. Orlistat (10 mg/kg) decreases serum cholesterol levels and total bod......

• Smiles:

  C([C@@H](OC([C@H](CC(C([2H])([2H])[2H])C)NC=O)=O)CCCCCCCCCCC)[C@H]1[C@H](CCCCCC)C(=O)O1

• Molecular Formula:

  C29H50D3NO5

• Molecular Weight:

  498.75

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  1356930-46-5